Sustainability led Clever Leaves emphasizes ESG-friendly, environmentally sustainable, low-cost production methods and has been awarded the International Declaration of Carbon Neutrality, signaling a strong sustainability story that can appeal to buyers prioritizing green supply chains.

Global B2B focus Operates as a multinational licensed producer of pharmaceutical-grade cannabinoids with a growing base of global B2B customers, presenting opportunities to expand API and finished product supply to new regional partners and contract manufacturers.

Strategic restructuring Recent asset sales and portfolio realignment, including divestment of Portugal operations and relocation activities, indicate potential for re-entry strategies, license opportunities, or partnerships in new or restructured European markets.

Colombia production hub Concentrated production in Colombia for cannabinoids API and finished products creates a foundation for nearshoring, scalable supply for Latin America, and potential regional expansion collaborations with local distributors and pharma manufacturers.

Collaborative growth Past and ongoing partnerships with Ethypharm and Australian Natural Therapeutics Group demonstrate openness to licensing, co-development, and distribution deals, suggesting ongoing sales opportunities via strategic alliances and market entry programs.